Yearly Archives: 2017

FDA Notifies Cambium Phase I/II Dry Eye Study Can Proceed

Study for Graft vs. Host Disease Dry Eye to Begin Late 2017/Early 2018 ATLANTA, GA – September 29, 2017 – Cambium Medical Technologies (“Cambium”), a clinical stage company, announced today that the U.S. Food & Drug Administration (“FDA”) notified Cambium on September 22 it has completed review of Cambium’s Investigational New Drug Application (IND) submitted ...
Read more